New research reveals that resistant myeloma cells import putrescine through the transporter SLC45A4, activating HOXA1-driven ...
With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
A phase 3 trial evaluates whether adding felzartamab to lenalidomide-dexamethasone improves progression-free survival in Chinese patients with relapsed or refractory multiple myeloma.
Clinical Trials Arena on MSN
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
BMS’s Zenbexus gained FDA approval based on a previous primary endpoint being achieved in the same trial.
A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...
A protocolized maintenance de-escalation permitted daratumumab cessation after ≥2 years plus ≥12 months sustained MRD negativity, with most patients not restarting at data cutoff. Generalizability is ...
A real-world study of fifty multiple myeloma patients found that high-dose melphalan with autologous stem cell ...
African American patients with newly diagnosed multiple myeloma were less likely than White patients to receive drugs that ...
Lady A singer Charles Kelley reveals his multiple myeloma diagnosis following unexpected rib fractures. Discover how the ...
A phase 1 clinical trial found that an investigational CAR-T therapy can lead to deep and durable responses in people with ...
Otero, MD, discusses findings from the LINKER-SMM1 trial presented at the IMS Annual Meeting. Paula Rodríguez-Otero, MD, consultant and deputy professor at the University of Navarra, Spain, discusses ...
Life with this blood cancer is rarely straightforward, but as one patient found, there’s a lot of hope for the future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results